



Forming of a Joint Venture with Accenture Co., Ltd. Accompanied by a Share Transfer of Shionogi Business Partner Co., Ltd.

OSAKA, Japan, February 20, 2023 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that, at the meeting of its Board of Directors held today, the Directors decided to transfer a portion of the shares of Shionogi Business Partner Co., Ltd., (Head Office: Osaka, Japan; President: Yuji Hosogai; hereafter "Shionogi Business Partner"), a wholly-owned group company, to Accenture Co., Ltd. (Head Office: Tokyo, Japan; Chief Executive Officer: Atsushi Egawa; hereafter "Accenture") to form a joint venture.

In its reorganization in July 2022, to improve business process efficiency, Shionogi merged four group companies running back office functions such as human resources, general affairs, accounting and finance into Shionogi Business Partner Co., Ltd.

In order to further accelerate business reforms and enhance the expertise of employees, we have decided to transfer 80% of Shionogi Business Partner's stock to Accenture and form a joint venture. The transfer is scheduled to be concluded on July 3, 2023. In addition, prior to the forming of this joint venture, Shionogi Pharmacovigilance Center Co., Ltd. (Head Office: Osaka, Japan; President: Masako Kaneto; hereafter "Shionogi Pharmacovigilance Center") will be absorbed into Shionogi Business Partner on July 1, 2023 for the purpose of synergy with Accenture's business process managed services related to safety management operations.

By forming a joint venture with Accenture, we will utilize Accenture's strength in indirect business reform know-how to thoroughly improve efficiency. Furthermore, by learning from Accenture's know-how, we will create new opportunities for the professional growth and development of the employees, enabling them to play a greater role in the growth and development of Shionogi Group's business.

Together with Shionogi Business Partner and Shionogi Pharmacovigilance Center, Accenture and Shionogi will continue working on the finer details of the establishment ahead of the planned July launch.

Outline of the joint venture

Corporate Name	Shionogi Business Partner Company Limited [SBP]
Location	7-6, Doshomachi 4-chome, Chuo-ku, Osaka
Start of operations	July 3, 2023 (planned)
Number of Staff	Approximately 420 (planned)
The main business	<ul style="list-style-type: none">Shared services Contracted services related to the Shionogi Group's following operations: personnel, administration, public relations, facility management, database management, accounting, finance, procurement, sales support, marketing support, education & training, career development support

	<ul style="list-style-type: none"> Safety management and post-marketing operations of the Shionogi Group as required by the Pharmaceuticals and Medical Devices Act and other regulation
Initial Capitalization	10 million yen
Investment ratio	Accenture 80%, Shionogi 20%

Company absorbed in the Merger

Shionogi Pharmacovigilance Center Company Limited (as of February 20, 2023)

Corporate Name	Shionogi Pharmacovigilance Center Company Limited [SPV]
Location	7-6, Doshomachi 4-chome, Chuo-ku, Osaka
Representative Person	Masako Kaneto
Date of Establishment	April 3, 2017
Number of Staff	81 (as of January, 2023)
Initial Capitalization	10 million yen
The main business	Safety management and post-marketing operations of the Shionogi Group as required by the Pharmaceuticals and Medical Devices Act and other regulation.

About Accenture

Accenture is a leading global professional services company that helps the world's leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services—creating tangible value at speed and scale.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

References

1. [Press release on May 23,2022](#)
Shionogi Announces appointment of Corporate officers, Corporate Reorganization and Personnel Reassignment

For Further Information, Contact:

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>